Clinigen's (CLIN) managed access division - where the group distributes early-stage medicines to patients with severe unmet needs - continues to benefit from the 2015 acquisition of Idis Pharmaceuticals. The company has signed a deal with European biotech group Horizon Pharma to make one of the latter group's drugs immediately available to patients.
IC TIP:
Buy
at
600p
The drug RAVICTI is an oral solution for the treatment of urea cycle disorder - an inherited metabolic disease which can lead to severely high levels of blood ammonia and can be life threatening. The medicine gained marketing approval from the European Medicines Agency (EMA) in September 2015, and will now be made available by Idis to patients in need prior to commercial launch.
